Cardiovascular considerations crucial for CML TKI patients

[News]

A review of BCR–ABL1 tyrosine kinase inhibitors highlights the need to consider cardiovascular adverse event risk profiles when prescribing for patients with chronic myeloid leukaemia.

More... (http://www.news-medical.net/news/20160122/Cardiovascular-considerations-crucial-for-CML-TKI-patients.aspx)